Altarea : No turn-around in sight
| Entry price | Target | Stop-loss | Potential |
|---|
|
€187 |
€207 |
€177 |
+10.7% |
|---|
Altarea's shares display attractive technical aspects to anticipate a comeback of the underlying trend.
Strengths● The company has a low valuation given the cash flows generated by its activity.
● This company will be of major interest to investors in search of a high dividend stock.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
● Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● The company's earnings growth outlook lacks momentum and is a weakness.
● Low profitability weakens the company.
● The company is in debt and has limited leeway for investment
● The group usually releases earnings worse than estimated.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
ALTAREA 
